• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

Bioengineer by Bioengineer
April 10, 2021
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes

IMAGE

Credit: MD Anderson Cancer Center

HOUSTON – Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer.

The findings were published today in Cancer Discovery and presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 by Michael Kim, M.D., assistant professor of Surgical Oncology and Genetics.

“To our knowledge, this is the first study to show how these two major genetic drivers work together to promote tumor growth and metastasis,” Kim said. “We learned that signaling downstream of mutant KRAS directly promotes mutant p53 activity. This discovery provides not only a new therapeutic target but unveils a vast transcriptional network that is activated downstream of these mutant proteins.”

Mutations in KRAS and TP53, the two most frequently mutated genes in all human cancers, co-occur in roughly 70% of patients with pancreatic cancer. Mutant KRAS, found in 95% of pancreatic cancers, leads to an activated protein that aberrantly triggers many downstream signaling pathways. Mutant TP53 results in the loss of the proteins’ tumor suppressor function, leaving the mutant protein capable of fueling additional oncogenic processes, such as metastasis.

Unfortunately, no current therapies are able to block the mutant forms of KRAS or p53 prevalent in pancreatic cancer, so there is a need to identify common, alternative therapeutic targets downstream of these proteins that could lead to more effective treatment regimens for pancreatic cancer, Kim explained.

To learn how mutant KRAS and p53 might be interacting, Kim’s team of researchers collaborated with Gigi Lozano, Ph.D., chair of Genetics, to develop a novel mouse model of pancreatic cancer that expresses oncogenic KRAS and mutant p53 specifically in tumor cells, leaving the tumor microenvironment unaltered.

In this model, the team observed more than twice as many metastatic lesions than was seen when p53 was genetically removed, suggesting that the mutant proteins together cause a significant increase in metastatic potential. With further study, the researchers discovered mutant KRAS activates CREB1, a transcription factor that then directly interacts with mutant p53 to promote the aberrant expression of hundreds of genes.

This activation results in the increased expression of FOXA1, which in turns creates a new cascade of events leading to increased activity of the Wnt/β-catenin pathway, both of which promote cancer metastasis.

Using an available small-molecule drug to target CREB1 in this model resulted in decreased expression of FOXA1, β-catenin and associated target genes, along with a corresponding reduction in metastases. While early, these findings suggest that targeting CREB1 may be a viable strategy to block the metastatic effects of mutant KRAS and p53 in pancreatic cancer.

“The identification of this cooperative node suggests that there should be increased focus on CREB1 as a target that could be therapeutically exploited to improve patient outcomes,” Kim said. “With the frequency of KRAS and TP53 mutations in human cancers, the implications of our findings may extend far beyond pancreatic cancer.”

Going forward, the researchers hope to discover other important elements working downstream of mutant p53 that may affect the cancer cells or the surrounding tumor microenvironment. A greater understanding of this complex network may point to additional therapeutic targets or combination approaches to better treat pancreatic cancer.

###

The research was supported by the National Institutes of Health (NIH) (K08CA218690, P01CA117969, R01CA82577, T32 CA 009599, 1S10OD024976-01, P30CA16672), the American College of Surgeons Faculty Research Fellowship, the Cancer Prevention & Research Institute of Texas (CPRIT) (RP17002), the Richard K. Lavine Pancreatic Fund, the Ben and Rose Cole Charitable Pria Foundation, and the Skip Viragh Foundation.

In addition to Kim, MD Anderson collaborators on the study include: Xinqun Li, M.D., Ph.D., Jenying Deng, Ph.D., Bingbing Dai, Ph.D., Tara G. Hughes, M.D., Christian Siangco, Jithesh Augustine, and Yaan Kang, M.D., all of Surgical Oncology; Yun Zhang, Ph.D., Joy M. McDaniel, Ph.D., Shunbin Xiong, Ph.D., Amanda R. Wasylishen, Ph.D., and Guillermina Lozano, Ph,.D., all of Genetics; Kendra Allton, Bin Liu, Ph.D., and Michelle C. Barton, Ph.D., all of Epigenetics and Molecular Carcinogenesis; Eugene Koay, M.D., Ph.D., of Radiation Oncology; Florencia McAllister, M.D., of Gastrointestinal Medical Oncology and Clinical Cancer Prevention; Christopher Bristow, Ph.D., and Timothy P. Heffernan, Ph.D., of the TRACTION platform; and Anirban Maitra, M.B.B.S., of the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research. Additional co-authors include Jason B. Fleming, M.D., of Moffitt Cancer Center and Research Institute, Tampa, FL. The authors declare no conflicts of interest.

Media Contact
Clayton Boldt
[email protected]

Tags: cancerCell BiologyGenesGeneticsMedicine/HealthMolecular Biology
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

New Research Explores the Brain as a Potential Target for Type 1 Diabetes Treatments

August 2, 2025
Macrophage-T Cell Interaction Boosts SLAMF1 in TB Defense

Macrophage-T Cell Interaction Boosts SLAMF1 in TB Defense

August 2, 2025

Strawberry Notch 1 Protects Neurons by Regulating Yeats4

August 2, 2025

What “And” vs. “Then” Reveal About Hospital Visits: Insights from Online Reviews

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10
  • Sustainability Accelerator Chooses 41 Promising Projects Poised for Rapid Scale-Up

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Research Explores the Brain as a Potential Target for Type 1 Diabetes Treatments

Macrophage-T Cell Interaction Boosts SLAMF1 in TB Defense

Strawberry Notch 1 Protects Neurons by Regulating Yeats4

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.